Healthcare / Drug Manufacturers - Specialty & GenericNSE
$274.85
+12.19 (+4.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.9B · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$72.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-46.7%
↓Gross Margin
100.0%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-19.3%
FCF CAGR
—
FCF margin
-4313.2%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $71.1M · net income $-2.76B · FCF $-3.07B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $71.1M | $71.1M | $66.6M | $116.9M | $135.4M |
| Net Income | $-2.76B | $-2.76B | $-1.61B | $-1.05B | $-1.18B |
| EBITDA | $-2.71B | $-2.71B | $-1.55B | $-994.2M | $-1.11B |
| EPS | -12.13 | -12.13 | -7.37 | -4.82 | -6.63 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 93.9% | 97.3% |
| Operating Margin | -4077.7% | -4077.7% | -2578.1% | -1148.5% | -974.3% |
| Net Margin | -3884.1% | -3884.1% | -2415.1% | -898.6% | -873.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | — | 0.00 | 0.00 |
| Current Ratio | 17.70 | 17.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.07B | $-3.07B | $-1.91B | $-826.2M | $-1.19B |
| Returns | |||||
| ROE | -46.7% | -46.7% | -146.1% | -38.9% | -31.5% |
| Valuation | |||||
| P/B | 10.59 | 10.59 | 25.53 | 9.06 | 2.96 |
| Growth & Yield | |||||
| Revenue Growth | 6.9% | 6.9% | -43.1% | -13.6% | — |
| EPS Growth | -64.6% | -64.6% | -52.9% | 27.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.37 → -12.13
Residual
+18.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.